66 results about "Actin" patented technology

The present invention relates to an adeno-associated virus (AAV) vector comprising in the 5' to 3' direction: a first AAV2 ITR sequence; a CMV enhancer sequence; a chicken β-actin promoter sequence; a nucleic acid sequence encoding an apolipoprotein 2 (APOE2) polypeptide comprising a Christchurch mutation; a polyA sequence; and a second AAV2 ITR sequence.

The invention belongs to the technical field of RNA biological prevention and treatment, and particularly relates to application of dsRNA of a targeted actin coding gene. The invention provides application of dsRNA of a targeted actin coding gene in prevention and treatment of crop anthracnose, the nucleotide sequence of the dsRNA is shown as SEQ ID No.2, the dsRNA is obtained by transcription of a target gene segment of a colletotrichum CaACTIN gene, and the nucleotide sequence of the target gene segment of the colletotrichum CaACTIN gene is shown as SEQ ID No.1. The dsRNA is loaded by a nano-material layered double hydroxide, so that the dsRNA can be applied to prevention and treatment of crop anthracnose, and the target gene segment of the colletotrichum CaACTIN gene is obtained through transcription of the target gene segment of the colletotrichum CaACTIN gene and the target gene segment of the colletotrichum CaACTIN gene. The pathogenicity of mango colletotrichum gloeosporioides and banana colletotrichum gloeosporioides can be obviously reduced, and the application prospect of efficient and targeted control of crop anthracnose is achieved.

The present disclosure relates to bifunctional compounds comprising targeting moiety that binds SWI / SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4 (SMARCA4) or SMARCA2 and SMARCA4, and a degron that binds an E3 ubiquitin ligase. The disclosure further provides compositions and methods for treating diseases or conditions mediated by aberrant activity of SMARCA4 or SMARCA2 and SMARCA4, including diffuse midline glioma harboring a H3K27M mutation.

The invention discloses a method for improving the efficiency of a baculovirus expression system. According to the invention, actin is overexpressed in insect BmN cells, so that the expression of exogenous genes is improved. The principle is as follows: after overexpression of actin, the recruitment efficiency of virus nucleation and late gene polymerase is improved, so that the replication and transcription of recombinant virus containing exogenous genes are promoted. According to the invention, the problem of low protein expression quantity by using the baculovirus is solved, ultrahigh-level expression of the protein is promoted, and the efficiency of a baculovirus expression system is improved.

This disclosure is based, at least in part, on unexpected discoveries that a novel composition of a leukotoxin (LtxA) polypeptide isolated from Aggregatibatier actin omycetcmcomitans can retain stability and biological activities for an extended period of time even after the composition, is subject to a process of lyophilization, storage, reconstitution, and / or further storage, or under an accelerated condition, and that a particular range of dosage of the LtxA polypeptide and administration regimen can provide high efficacy and low toxicity in treating cancer in a patient in need thereof.

The invention provides a genetically engineered bacterium for efficiently producing pseudouridine and application of the genetically engineered bacterium. The genetically engineered bacterium is based on a high-yield uridylic acid strain E. coli MB219 (the patent application number is 202410153359.6), and the high-efficiency pseudouridine engineering bacterium is constructed through systemic gene modification. The genetically engineered bacterium is characterized in that (1) gene knockout: 10 genes such as pbs1, psuK and the like are knocked out to block a metabolic pathway of byproducts; (2) metabolism regulation: replacing a J23110 strong promoter, and overexpressing zwf / gnd to enhance a phosphopentose pathway; (3) heterologous gene integration: integrating a specific dephosphorylase gene HDHD1, and introducing RjpsuG, NmygdH and thyA to construct a co-expression plasmid pRL06; the fermentation yield of the finally obtained engineering bacterium CY20 (pRL06) reaches 45.3 g / L and is increased by 6 times compared with that of a traditional method, the production efficiency is greatly improved, the product purity is high, and by-products are few.

The invention discloses a diabetic nephropathy marker PARP1, a primer combination and application, and relates to the technical field of biology. The sequence of the primer combination is PARP1-F, and is as shown in SEQ ID NO. 1; 1, PARP1-R as shown in SEQ ID NO. 2; an internal reference primer beta-actin-F, which is as shown in SEQ ID NO. 17; an internal reference primer beta-actin-R is as shown in SEQ ID NO. 18. The invention finds that the expression of PARP1 in the kidney tissue of a patient with diabetic nephropathy is increased and is positively correlated with ACR (Activated Receptor). The invention also finds that PARP1 is related to podocyte damage, and knocking down PARP1 can relieve podocyte endoplasmic reticulum stress and apoptosis, and can reflect the progress of DKD to a certain extent.

Herein is reported a method for classifying cells in a mixture of cells wherein the mixture comprises T cells and B cells, the method comprising the steps of: first, applying a labeled antibody binding to at least F-actin, MHCII and CD3 to the mixture of cells to obtain a labeled mixture of cells, wherein the antibodies are each labeled with a dye wherein the dyes have different (non-overlapping) emission wavelengths, second, acquiring at least one image of the mixture of cells, and third, classifying the cells in the mixture of cells as isolated cells, if the cells are single cells, are F-actin positive, if the cells are F-actin positive, and if the cells are not F-actin positive, the cells are not F-actin positive. And is MHCII positive and CD3 negative, or is MHCII negative and CD3 positive; or a diad or concatemer of cells, if the cell is an aggregate of two or three cells, the cell is F-actin positive, MHCII positive and CD3 positive, or a diad or concatemer of the cells, if the cell is an aggregate of two or three cells, is F-actin positive, MHCII positive and CD3 positive.

The invention belongs to the technical field of biological medicine, and discloses a protein nanomotor based on disulfide death and a preparation method and application thereof. The invention discloses a protein nanomotor, which comprises cystine or pharmaceutically acceptable salts thereof, and an enzyme connected with the cystine or the pharmaceutically acceptable salts thereof, the enzyme comprises glucose oxidase and an enzyme with a matrix degradation function, and the protein nano motor provided by the invention can trigger disulfide death of tumor (such as lung cancer) cells, so that a cell actin skeleton generates a large number of disulfide bonds and seriously shrinks, and finally, the cell structure comprehensively collapses and dies. Therefore, efficient killing of tumors is realized. Through synergistic effects of microenvironment remodeling, self-driven intra-tumor penetration promotion and disulfur death induction, the tumor treatment effect is significantly enhanced.

The present invention relates to bispecific binding agents comprising an F-actin binding moiety and an Fc domain for use in medicine, which allows for simultaneous binding of an Fc receptor and F-actin. This allows necrotic cell antigens to be presented to the immune system. The invention also provides bispecific binding agents and methods of using the agent to identify a tumour antigen.

The present invention features promoters providing for DNA transcription. The promoters comprise: (1) a promoter core derived from the human peptidyl-prolyl isomerase G (PPIG) promoter, ATP citrate lyase (ACLY) promoter, actin gamma (ACTG1) promoter, actin related protein 2 (ACTR2) promoter, actin related protein 2 / 3 complex subunit 2 (ARPC2) promoter, or the vinculin (VCL) promoter; and / or (2) ocular specific transcription factor binding motifs from CRX, OTX2, and / or NRL.

The claimed group of inventions relates to the field of medicine, more precisely to gene therapy for a disease that is incurable as of the date of submission of the application materials - metachromatic leukodystrophy (MLD), which is a severe hereditary neurodegenerative disease that occurs due to deficiency of the lysosomal enzyme arylsulfatase A (ARSA). The essence of the technical solution is a recombinant genetic construct containing CMV / chicken β-actin hybrid enhancer promoter and the codon-optimized ARSA gene sequence represented by SEQ ID NO: 1. Adeno-associated virus of serotype Olig001 for the treatment of metachromatic leukodystrophy, containing a recombinant genetic construct according to claim 1.

The invention belongs to the technical field of cell biology, and provides an oocyte in-vitro maturation culture solution additive and application thereof. Experimental results show that coumarin 106 can improve the retardation of the meiosis process of oocytes, reduce the form proportion of abnormal spindles of oocytes and the proportion of wrongly arranged chromosomes, recover the level of acetylated tubulin and improve the stability of microtubules; the actin expression level in the spindle body of the oocyte is improved; the conditions of wrong distribution and expression decline of mitochondria in oocytes are improved; the mitochondrial membrane potential level is improved; fluorescence signals of oocyte cortical particle and specific cortical particle protease are improved; the fertilization rate is improved; the active oxygen level and the DNA damage level in the oocytes are reduced, and the occurrence of early apoptosis in the oocytes is reduced. A culture solution prepared from the coumarin 106 can be used for promoting in-vitro maturation of oocytes.

The invention provides a reference gene combination for real-time fluorescent quantitative PCR (Polymerase Chain Reaction) of indocalamus as well as a primer pair combination and application of the reference gene combination, and belongs to the technical field of plant molecular biology. In combination with indocalamus transcriptome data analysis and cross validation of four algorithms, reference genes, MD10B, PP2A, eIF1A, Ite23725, eIF4A, 60S and UBP1, suitable for indocalamus are systematically screened out, optimal reference gene combinations under different experimental conditions (drought, salt, waterlogging stress and different tissues) are refined, and the method is scientific and rigorous and has good application prospects. And a precise tool is provided for gene expression analysis of the indocalamus in different research directions. The screened reference genes show extremely high expression stability in specific stress and tissues after being combined, and the expression stability is far better than that of traditional housekeeping genes such as Actin and UBI. The specific primer has high amplification efficiency, and ensures the accuracy of qRT-PCR results.

The application belongs to the technical field of cell biology, and provides an oocyte in vitro maturation culture medium additive and application thereof. The experimental results of the application show that coumarin 106 can improve the meiosis process blockage of oocytes, reduce the morphological proportion of abnormal spindle and the proportion of misaligned chromosomes, restore the level of acetylated tubulin, improve microtubule stability, improve the expression level of actin in the spindle of oocytes, improve the misdistribution and expression decrease of mitochondria in oocytes, improve the level of mitochondrial membrane potential, improve the fluorescence signal of cortical granules and specific cortical granule proteases in oocytes, improve the fertilization rate, reduce the level of reactive oxygen species and DNA damage in oocytes, and reduce the occurrence of early apoptosis in oocytes. The culture medium prepared by using coumarin 106 can be used for promoting oocyte in vitro maturation.

In some aspects, the present disclosure relates to methods and compositions for quality control (e.g., assessing the immobilization level of a biological sample) and / or optimizing the detection of an analyte in an immobilized sample. In some embodiments, the method can be used to treat an immobilized biological sample, the method comprising contacting the immobilized biological sample with a nucleic acid stain and / or an actin stain; detecting a light signal associated with the nucleic acid stain and / or a light signal associated with the actin stain; the detected light signal is compared to one or more references to determine the quality of the biological sample. Single cell analysis, spatial array-based analysis, or in situ analysis may be performed using the treated biological sample.

Provided herein are recombinant self-complementary adeno-associated virus (scAAV) nucleic acid vectors containing ubiquitous eukaryotic promoters, such as elongation factor 1 alpha (EF1α), chicken beta-actin (CBA), and hybrid chicken beta-actin (CBh), followed by a dominant-negative RhoA. Also provided herein are methods of using the vectors, including intraocular injection (e.g., intracameral injection) to reduce intraocular pressure (IOP). Also provided herein are plasmids, recombinant scAAV particles, compositions, formulations, and other methods of use related to such vectors.

The present invention discloses a recombinant turkey herpes virus strain expressing H9 subtype AIV HA gene and IBV S gene and its application, belonging to the technical field of medicine or veterinary medicine. The recombinant turkey herpes virus strain is obtained by inserting an expression frame comprising a chicken β-actin promoter, AIV HA gene and IBV S gene coding sequences, a woodchuck hepatitis virus post-transcriptional regulatory sequence, and a rabbit β-globulin polyadenylic acid sequence into the HVT genome. The recombinant virus strain obtained by the present invention has good in vitro replication ability and genetic stability. After immunizing SPF chickens, the SPF chickens can obtain immune protection against H9 subtype AIV and QX type IBV. The present invention provides a new technical means for preventing H9 subtype avian influenza and chicken infectious bronchitis at the same time.

Disclosed are compounds of Formula I, or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers thereof, which are useful for modulating or degrading proteins expressed by one or more SWI / SNF related matrix associated actin dependent chromatin regulatory factor A subfamily (SMARCA) (e.g., SMARCA2 and / or SMARCA4). I

The invention discloses an application of a compound EG-011 and a pharmaceutical composition thereof in resisting influenza A virus. It is found for the first time that EG-011 treated cells can increase the density of actin branches so as to prevent IAV from being transported from plasma membranes to cell nucleuses, and proliferation of IAV in host cells is effectively inhibited. In-vivo experiments prove that the EG-011 can significantly inhibit the proliferation of IAV in the body of a mouse and improve the survival rate of the mouse. The EG-011 has a clear action mechanism, has a good anti-influenza effect, can be used as a lead compound of a novel anti-influenza virus drug, and has a wide application prospect.

Protein biosensors for drug discovery, such as a high-throughput assay utilizing TR-F to detect the properties of binding proteins (e.g., actin-binding proteins, ABPs) using a fluorescence lifetime plate reader and fluorescent probes. In particular, the present invention is a new use of TR-F technique to rapidly evaluate binding of F-actin (− or +Tm) with cMyBP-C in solution. Changes in labeled actin fluorescence lifetime due to cMyBP-C phosphorylation and / or HCM mutations correlated with binding measured by traditional cosedimentation. The present invention features methods for HTS for identifying molecules that modulate cMyBP-C or cMyBP-C-actin complex.

The invention provides a primer for specifically detecting genome DNA residues in sisal hemp cDNA and a method and application thereof. According to the invention, a beta-ACTIN gene is found in housekeeping genes stably expressed in each tissue of sisal hemp, and a unique sequence difference exists in the beta-ACTIN gene of the sisal hemp by comparing a DNA sequence and a cDNA sequence of the genome. On the basis, a pair of specific primers is developed, cDNA and gDNA of the sisal hemp can be clearly distinguished in common agarose gel electrophoresis on the basis of the length difference of amplified fragments, and gDNA pollution residues can be accurately detected in sisal hemp of different sources and varieties. The detection primer has the advantages of being high in specificity, good in stability, high in universality, simple in detection method, economical, practical and the like, and an efficient and specific standardized quality control tool is provided for evaluating sisal hemp RNA extraction quality and guaranteeing reliability of subsequent molecular experiment data.

The present invention relates to a biomarker for measuring anticancer drug resistance comprising a gene expressed in a group of cancer cells, wherein the gene releases an anticancer drug that has penetrated into the group of cancer cells to the outside of the group of cancer cells, wherein the gene comprises a gene selected from the group consisting of ABCG1, p-STAT3, STAT3, p-AKT, AKT, p-ERK, ERK, β-actin, ACTA2, GAS6, FAP, PDPN, COL1A1, AXL, and combinations thereof.

The invention belongs to the technical field of polysaccharides, and particularly discloses application of sulfated seaweed polysaccharides in preparation of anti-hepatic fibrosis drugs. According to a structural unit of the seaweed sulfated polysaccharide SPW-05-S2, 1, 4-beta-glucuronic acid and 1, 2-alpha-mannose are alternately connected to form a main chain, mannose, xylose, galactose and fucose form branch chains, the branch chains are located on the C-6 site and the C-3 site of the 1, 2-alpha-mannose, and the branch chains are located on the C6 site and the C-3 site of the 1, 2-alpha-mannose. The branches consist of galactose residues, xylose residues, mannose residues and fucose residues. In-vitro experiments prove that the polysaccharide can be used for remarkably inhibiting the expression of fibrosis related proteins (Fibronectin, Collagen I and alpha-smooth muscle actin), and can be used for remarkably inhibiting the expression of the fibrosis related proteins (Fibronectin, Collagen I and alpha-smooth muscle actin). Meanwhile, the surface plasmon resonance technology finds that the polysaccharide can be combined with PI3K protein. Therefore, the polysaccharide has a potential anti-hepatic fibrosis effect and is expected to become a candidate saccharide drug for treating hepatic fibrosis.

The present disclosure relates to double-stranded ribonucleic acid (dsRNAi) agents and compositions that target the actin-binding LIM protein 3 (ABLIM3) gene, methods of inhibiting the expression of the ABLIM3 gene, and methods of treating a subject having an ABLIM3-related disease or disorder, such as PTSD or age-related memory loss, using such dsRNAi agents and compositions.

The invention relates to the technical field of biology, in particular to an lncRNA primer group for detecting apis cerana infected by bee glomus and application of the lncRNA primer group, and the primer group comprises the following primers: lncRNA6470-F, lncRNA6470-R, Ace-actin-F and Ace-actin-R; the nucleotide sequence of the lncRNA6470-F is as shown in SEQ ID No. 1 (sequence identifier number 1); the nucleotide sequence of the lncRNA6470-R is as shown in SEQ ID No. 2; the nucleotide sequence of the Ace-actin-F is as shown in SEQ ID No. 3; and the nucleotide sequence of the Ace-actin-R is as shown in SEQ ID No. 4. The research finds and identifies a specific lncRNA molecule, namely lncRNA6470, of which the expression is obviously changed after worker bee larvae of apis cerana are infected by bee glomus, the primer group provided by the research can be used for early diagnosis of the apis cerana chalkbrood disease, the diagnosis time is earlier than that of a traditional method, a diagnosis basis can be provided for whether bee colony larvae are infected by chalkbrood disease or not before the larvae are attacked, and the method has the advantages that the method is simple and convenient to operate, and the cost is low. A new view angle and a new target spot are provided for clarification of a molecular mechanism of Chinese bee chalkbrood disease resistance, and a theoretical foundation is laid for development of a novel bee disease prevention and control technology based on RNA interference in the future.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of Tim-4 in diagnosis and treatment of osteoporosis. Specifically, it is found through research that reduction of the expression level of Tim-4 is related to occurrence of osteoporosis, Tim-4 deficiency promotes differentiation and functions of osteoclasts so as to aggravate phenotypes of mouse osteoporosis, and Tim-4 deficiency has no obvious influence on bone forming ability. Lysosome pathways in the Tim-4-deleted osteoclast are remarkably enriched, and it is preliminarily proved that the number of lysosomes in the Tim-4-deleted osteoclast is increased, and the function of the Tim-4-deleted osteoclast is enhanced. It is further found that overexpression of Tim-4 inhibits the progression of osteoporosis. The specific effect of Tim-4 in osteoporosis is defined for the first time, and a new target is provided for osteoporosis intervention by regulating osteoclasts, so that the application has good practical application value.

Disclosed are compounds of Formula I, or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers thereof, useful for regulating or degrading proteins expressed from one or more SWI / SNF-related matrix-associated actin-dependent regulators of chromatin subfamily A (SMARCA) (e.g., SMARCA2 and / or SMARCA4). TIFF2025525340000430.tif52170

This invention belongs to the field of parasite detection technology, specifically relating to a lyophilized PCR kit for detecting Clonorchis sinensis in fecal samples. The lyophilized PCR kit of this invention includes a lyophilized reaction powder, a positive control, a negative control, and a reconstitution solvent. The lyophilized reaction powder is prepared by freeze-drying a reaction solution containing the following components: (a) a first primer pair and a first probe for detecting the Clonorchis sinensis COX1 gene; (b) a second primer pair and a second probe for detecting the human genomic actin (ACT) gene; (c) PCR reaction components: including hot-start Taq DNA polymerase, dNTPs, and a buffer system; and (d) a lyophilization protectant. This invention targets the Clonorchis sinensis-specific COX1 gene and uses PCR amplification technology to detect fecal samples, accurately identifying Clonorchis sinensis nucleic acid and effectively avoiding cross-reactions with other parasites and intestinal flora. The detection specificity and sensitivity are significantly improved, and the repeatability and stability are excellent.

The invention belongs to the field of biological medicines, and particularly relates to a qRT-PCR (quantitative reverse transcription-polymerase chain reaction) kit for rapidly detecting lung squamous cell carcinoma or early lung cancer as well as application and a detection method of the qRT-PCR kit. The kit comprises a reverse transcription reagent, a PCR reaction reagent and a reference substance, wherein the PCR reaction reagent comprises upstream and downstream primers of lung cancer related genes and upstream and downstream primers of reference genes; an upstream primer and a downstream primer of the lung cancer related gene comprise the following primer pairs: SSBA-F: 3 '-TGCTTCTAGTGGGCTCGG-5', 3 '- The invention discloses a kit for diagnosing subtypes of lung cancer and squamous cell lung cancer, which comprises a reference gene, an upstream primer and a downstream primer of the reference gene, and the upstream primer and the downstream primer of the reference gene comprise the following primer pairs: Actin-F: 3 '-CCACGAGGGGTTCACCGGGG-5' and Actin-R: 3 '-GTGATCTCTTCTGCATCTGGT-5'. The kit provided by the invention can realize rapid, minimally invasive and low-consumption diagnosis of the subtypes of the early lung cancer and squamous cell lung cancer, grasp the precedent of treatment and improve the patient dependency at the same time, and is favorable for improving the survival rate and the living quality of the patient.